Expertise in
14
conditions

Sara Lonardi

Padova, IT 
Expertise in
14
conditions
Padova, IT 
OverviewLocationsClinical Research

Overview

Sara Lonardi practices in Padova, Italy. Ms. Lonardi is highly rated in 14 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Stomach Cancer, Tissue Biopsy, and Liver Transplant.

Her clinical research consists of co-authoring 479 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Padova, Italy
Other Locations
Genoa, Italy
Padova, Italy
Brescia, Italy
Veneto, Italy
Verona, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
First-line Combination of Capecitabine and Oxaliplatin + Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
First-line Combination of Capecitabine and Oxaliplatin + Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
Enrollment Status: Unknown
Publish Date: November 29, 2023
Intervention Type: Drug
Prognostic Value of Baseline G8 Geriatric Assessment in Elderly Metastatic Colorectal Cancer Patients
Prognostic Value of Baseline G8 Geriatric Assessment in Elderly Metastatic Colorectal Cancer Patients
Enrollment Status: Unknown
Publish Date: November 29, 2023
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Enrollment Status: Unknown
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: CAPOX, Capecitabine, FOLFIRI
Study Phase: Phase 2
Immunophenotyping of Metastases From Colorectal Cancer
Immunophenotyping of Metastases From Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 20, 2020
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients
Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients
Enrollment Status: Unknown
Publish Date: May 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE
A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE
Enrollment Status: Unknown
Publish Date: February 15, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

479 Total Publications

Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN.
Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lonardi's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile